Endocrine Abstracts (2010) 22 OC3.4

Influence of the d3-GH receptor polymorphism on the metabolic and biochemical phenotype of GH deficient adults at baseline and during short- and long-term rhGH replacement therapy

Claudia Giavoli1, Emanuele Ferrante1, Eriselda Profka1, Luca Olgiati1, Silvia Bergamaschi1, Cristina L Ronchi1, Elisa Verrua1, Marcello Filopanti1, Elena Passeri2, Laura Montefusco3, Andrea G Lania1, Sabrina Corbetta2, Maura Arosio3, Bruno Ambrosi2, Anna Spada1 & Paolo Beck Peccoz1


1Endocrinology and Diabetology Unit, Department of Medical Sciences, University of Milan, Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico, Milan, Italy; 2Endocrinology Unit, Department of Medical and Surgical Sciences, University of Milan, Policlinico San Donato IRCCS, Milan, Italy; 3Unit of Endocrinology, University of Milan, Ospedale San Giuseppe Milan, Milan, Italy.


A common polymorphic variant of the GH receptor (exon-3 deletion, d3GHR) has been linked with increased response to recombinant human GH (rhGH) in some, but not all, GH deficient (GHD) and non-GHD patients. Aim of this study was to investigate the impact of the GHR genotype on the phenotype of GHD adults and on the metabolic effect of short- and long-term rhGH therapy, with particular focus on glucose homeostasis (1 year: n=100 and 5 years: n=50). Effects of rhGH on IGF1 serum levels, body composition (BF%), BMI, lipid profile and glucose homeostasis (fasting insulin and glucose, insulin sensitivity determined by HOMA and QUICKI) were evaluated according to the presence or absence of the d3GHR variant. Forty-eight percent of patients had two wild-type alleles (fl/fl), 45% one allele and 7% two alleles encoding the d3GHR isoform. Patients bearing at least one d3 allele (d3/d3 or d3/fl) were grouped together and indicated as d3GHR. The different genotype did not influence the phenotype of GHD adults at baseline. Short-term rhGH determined normalization of IGF1 levels, decrease in BF% and transient worsening of insulin sensitivity, independently from the presence of the d3GHR allele. A significant increase in HDL cholesterol occurred only in the d3GHR group (from 50±16 to 55±18 mg/dl, P<0.05). Concerning long-term effects, normalization of IGF1 levels and decrease of BF% maintained after 5 years. Insulin sensitivity restored to baseline values, though in d3GHR patients fasting glucose remained significantly higher than at baseline. Moreover, both after 1 and 5 years, proportion of subjects with impaired glucose tolerance, similar in the 2 genotype-groups at baseline, decreased in fl/fl while doubled in d3GHR patients. In this last group a long-term significant reduction of total and LDL cholesterol was also observed (from 208±50 to 188±41 mg/dl and from 136±35 to 105±53, respectively, P<0.05). In conclusion, present results seem to support the view that functional difference of d3GHR may influence at least some of the metabolic effects of rhGH in GHD adults.

Article tools

My recent searches

No recent searches.